Pharmafile Logo

News and Press Releases

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s TECARTUS (brexucabtagene autoleucel) in patients with aggressive blood cancers

At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-term Response in Adult Patients with Relapsed/Refractory(R/R) Mantle Cell Lymphoma (MCL) Real-world...

Category: Clinical Trials
Posted: December 12, 2023

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Kite’s CAR T-Cell Therapy YESCARTA (Axicabtagene Ciloleucel) Compared with Bispecifics in R/R DLBCL in Two Analyses at ESMO 2023

23 October 2023 -- Stockley Park, UK -- Kite, a Gilead Company, today announced results from two indirect comparative analyses of its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) versus bispecific...

Category: Clinical Trials
Posted: October 23, 2023

Kite Pharma
2400 Broadway Santa Monica, CA 90404

Kite’s CAR T-Cell Therapy Accepted for Use on the NHS in Scotland to Treat Aggressive Form of Blood Cancer

First CAR T-cell therapy for adult (26+) patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) reimbursed in Scotland 9 October 2023 -- London, UK -- Gilead Sciences...

Category: Pharmaceutical
Posted: October 9, 2023

Gilead Sciences, Inc